Browse by Title

Type here to filter the list

T
Target Trial Emulation with Real World Evidence: Regulatory Grade Pharmacoepidemiology in the SIGMA consortium

Ulrike Haug, PhD – Leibniz Institute for Prevention Research and Epidemiology - BIPS ### 1062658###Lead Speaker###Prof. Dr. sc. hum.###Leibniz Institute for Prevention Research and Epidemiology - BIPS###
Lead Speaker: Ulrike Haug, PhD – Leibniz Institute for Prevention Research and Epidemiology - BIPS
### @@@ Juan Jose Abellan, MSc, PhD – European Medicines Agency ### 1991548###Speaker###Biostatistics and RWE Senior Specialist###European Medicines Agency###
Speaker: Juan Jose Abellan, MSc, PhD – European Medicines Agency
### @@@ Vera Ehrenstein, MPH, DSc – Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital ### 1062544###Speaker###Professor###Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital###
Speaker: Vera Ehrenstein, MPH, DSc – Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital
### @@@ Buket Öztürk Esen, MSc, PhD (she/her/hers) – Aarhus University, Aarhus, Denmark ### 1062595###Speaker###Postdoctoral Researcher###Aarhus University, Aarhus, Denmark###
Speaker: Buket Öztürk Esen, MSc, PhD (she/her/hers) – Aarhus University, Aarhus, Denmark
### she/her/hers @@@ Vanessa Didelez, PhD (she/her/hers) – Leibniz Institute for Prevention Research and Epidemiology - BIPS ### 2325330###Speaker###Professor of Statistics and Causal Inference###Leibniz Institute for Prevention Research and Epidemiology - BIPS###
Speaker: Vanessa Didelez, PhD (she/her/hers) – Leibniz Institute for Prevention Research and Epidemiology - BIPS
### she/her/hers @@@ Wiebke Schäfer, PhD – Leibniz Institute for Prevention Research and Epidemiology - BIPS ### 1062894###Speaker###Post-doctoral researcher###Leibniz Institute for Prevention Research and Epidemiology - BIPS###
Speaker: Wiebke Schäfer, PhD – Leibniz Institute for Prevention Research and Epidemiology - BIPS
### @@@ Jonas Reinold, MSC, PhD (he/him/his) – Department Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS ### 1062999###Speaker###Head of Unit###Department Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS###
Speaker: Jonas Reinold, MSC, PhD (he/him/his) – Department Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS
### he/him/his @@@ David Martinez, MSc – RTI Health Solutions ### 1658516###Speaker###Senior Statistician###RTI Health Solutions###
Speaker: David Martinez, MSc – RTI Health Solutions
### @@@ Xabier Garcia de Albeniz Martinez, MD, PhD – RTI Health Solutions ### 1062596###Speaker###Director, Epidemiology###RTI Health Solutions###
Speaker: Xabier Garcia de Albeniz Martinez, MD, PhD – RTI Health Solutions
### @@@ Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy ### 1302758###Speaker###Head of Unit at ARS Toscana, Florence, Italy###ARS Toscana, Florence, Italy###
Speaker: Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy
### she/her/hers @@@ Oisin Ryan, PhD – University Medical Center Utrecht, Utrecht, the Netherlands ### 2325279###Speaker###Assistant Professor###University Medical Center Utrecht, Utrecht, the Netherlands###
Speaker: Oisin Ryan, PhD – University Medical Center Utrecht, Utrecht, the Netherlands
### @@@ Jessica C. Young, PhD (she/her/hers) – CAUSALab at IMM, Karolinska Institutet ### 1932107###Speaker###Postdoctoral Researcher###CAUSALab at IMM, Karolinska Institutet###
Speaker: Jessica C. Young, PhD (she/her/hers) – CAUSALab at IMM, Karolinska Institutet
### she/her/hers
The association between exposure to GLP-1 receptor agonists and risk of suicide-related and self-harm-related events in diabetic patients from the UK general practice IQVIA Medical Research Data (IMRD) database

Andrei Barbulescu, PhD (he/him/his) – European Medicines Agency ### 2325485###Presenting Author###pharmacoepidemiologist###European Medicines Agency###
Presenting Author: Andrei Barbulescu, PhD (he/him/his) – European Medicines Agency
### he/him/his @@@ María Clara Restrepo-Méndez, PhD – European Medicines Agency ### 1992322###Co-Author###Pharmacoepidemiologist###European Medicines Agency###
Co-Author: María Clara Restrepo-Méndez, PhD – European Medicines Agency
### @@@ Daniel R. Morales, PhD – European Medicines Agency ### 1062632###Co-Author###pharmacoepidemiologist###European Medicines Agency###
Co-Author: Daniel R. Morales, PhD – European Medicines Agency
### @@@ Robert Flynn, PhD – European Medicines Agency, University of Dundee ### 1658035###Co-Author###pharmacoepidemiologist###European Medicines Agency, University of Dundee###
Co-Author: Robert Flynn, PhD – European Medicines Agency, University of Dundee
###
The Association between Oral Antibiotic Use and Asthma Exacerbation in Children seen in an Ambulatory Care Setting

Carmen Canete Ramirez, PharmD (she/her/hers) – University of Montreal ### 2325334###Presenting Author###MSc Student###University of Montreal###
Presenting Author: Carmen Canete Ramirez, PharmD (she/her/hers) – University of Montreal
### she/her/hers @@@ Ana C Blanchard, MD, MSc – University of Montreal ### 2325386###Co-Author######University of Montreal###
Co-Author: Ana C Blanchard, MD, MSc – University of Montreal
### @@@ Amélie Forget, MSc – University of Montreal ### 2325387###Co-Author######University of Montreal###
Co-Author: Amélie Forget, MSc – University of Montreal
### @@@ Marie-Élaine Métras, PharmD, MSc – University of Montreal ### 2325388###Co-Author######University of Montreal###
Co-Author: Marie-Élaine Métras, PharmD, MSc – University of Montreal
### @@@ Tibor Schuster, PhD – McGill University ### 1093618###Co-Author######McGill University###
Co-Author: Tibor Schuster, PhD – McGill University
### @@@ Lucie Blais, PhD – University of Montreal ### 2325389###Co-Author######University of Montreal###
Co-Author: Lucie Blais, PhD – University of Montreal
### @@@ Cristina Longo, PhD – University of Montreal ### 2325390###Co-Author######University of Montreal###
Co-Author: Cristina Longo, PhD – University of Montreal
###
The Comparative Risk of Urinary Tract Infections with Degarelix and Gonadotropin-Releasing Hormone Agonists among Patients Diagnosed with Prostate Cancer: A Population-Based Cohort Study

Farzin Khosrow-Khavar, PhD – Rutgers University ### 2325383###Presenting Author###Instructor###Rutgers University###
Presenting Author: Farzin Khosrow-Khavar, PhD – Rutgers University
### @@@ Elisa Bandera, MD, PhD – Rutgers Cancer Institute of New Jersey ### 2325384###Co-Author######Rutgers Cancer Institute of New Jersey###
Co-Author: Elisa Bandera, MD, PhD – Rutgers Cancer Institute of New Jersey
### @@@ Chintan Dave, PharmD, PhD – Rutgers University ### 1655382###Co-Author###Assistant Professor of Pharmacy and Epidemiology###Rutgers University###
Co-Author: Chintan Dave, PharmD, PhD – Rutgers University
###
The effect of influenza vaccination on risk of myocardial infarction (MI) in patients taking statins: a self-controlled case series study

William E. Henley – University of Exeter ### 1660061###Presenting Author######University of Exeter###
Presenting Author: William E. Henley – University of Exeter
### @@@ Adam Streeter – Universität Münster ### 1991740###Co-Author######Universität Münster###
Co-Author: Adam Streeter – Universität Münster
###
The effectiveness of adalimumab biosimilars and originator for the treatment of Psoriasis: A target trial emulation study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Duc Binh Phan, MSc – Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom. ### 2326723###Presenting Author###PhD Student###Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.###
Presenting Author: Duc Binh Phan, MSc – Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.
### @@@ Anthony Bewley – Barts Health NHS Trust and Queen Mary University of London Medical School, London, United Kingdom. ### 2330952###Co-Author######Barts Health NHS Trust and Queen Mary University of London Medical School, London, United Kingdom.###
Co-Author: Anthony Bewley – Barts Health NHS Trust and Queen Mary University of London Medical School, London, United Kingdom.
### @@@ Philip Laws – Department of Dermatology, University of Leeds, Leeds, United Kingdom. ### 2330953###Co-Author######Department of Dermatology, University of Leeds, Leeds, United Kingdom.###
Co-Author: Philip Laws – Department of Dermatology, University of Leeds, Leeds, United Kingdom.
### @@@ Teena Mackenzie – Royal Berkshire NHS Foundation Trust, Reading, United Kingdom. ### 2330954###Co-Author######Royal Berkshire NHS Foundation Trust, Reading, United Kingdom.###
Co-Author: Teena Mackenzie – Royal Berkshire NHS Foundation Trust, Reading, United Kingdom.
### @@@ Catherine Smith – St Johns Institute of Dermatology, Guys & St Thomas NHS Foundation Trust, Kings College London, London, United Kingdom. ### 2328472###Co-Author######St Johns Institute of Dermatology, Guys & St Thomas NHS Foundation Trust, Kings College London, London, United Kingdom.###
Co-Author: Catherine Smith – St Johns Institute of Dermatology, Guys & St Thomas NHS Foundation Trust, Kings College London, London, United Kingdom.
### @@@ Christopher Griffiths – Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, Department of Dermatology, King’s College Hospital, King’s College London, London, United Kingdom. ### 2330955###Co-Author######Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, Department of Dermatology, King’s College Hospital, King’s College London, London, United Kingdom.###
Co-Author: Christopher Griffiths – Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, Department of Dermatology, King’s College Hospital, King’s College London, London, United Kingdom.
### @@@ Mark Lunt – Versus Arthritis Epidemiology Unit, The University of Manchester, Manchester, United Kingdom ### 2326729###Co-Author######Versus Arthritis Epidemiology Unit, The University of Manchester, Manchester, United Kingdom###
Co-Author: Mark Lunt – Versus Arthritis Epidemiology Unit, The University of Manchester, Manchester, United Kingdom
### @@@ Richard B Warren – Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom. ### 2326732###Co-Author######Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.###
Co-Author: Richard B Warren – Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.
### @@@ Zenas Zee Ngai Yiu – Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom. ### 2326733###Co-Author######Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.###
Co-Author: Zenas Zee Ngai Yiu – Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.
###
The Evolving Landscape of Drug Safety: Research, Reporting, and Real-World Outcomes

Amir Sarayani, PhamrD, MPH, PhD (he/him/his) – Janssen Research & Development, Johnson & Johnson ### 2325185###Moderator###Associate Director###Janssen Research & Development, Johnson & Johnson###
Moderator: Amir Sarayani, PhamrD, MPH, PhD (he/him/his) – Janssen Research & Development, Johnson & Johnson
### he/him/his @@@ Peter GM Mol, PhD PharmD (he/him/his) – Dutch Medicines Evaluation Board ### 1659255###Moderator###Professor of drug regulatory science###Dutch Medicines Evaluation Board###
Moderator: Peter GM Mol, PhD PharmD (he/him/his) – Dutch Medicines Evaluation Board
### he/him/his
The extent and magnitude of bias in case-crossover studies of real-world non-transient medications patterns: a simulation study with real-world examples

Hsiao-Ching Huang, MPH, PhD – Reagan-Udall Foundation for the FDA ### 2325458###Presenting Author###Research Scientist###Reagan-Udall Foundation for the FDA###
Presenting Author: Hsiao-Ching Huang, MPH, PhD – Reagan-Udall Foundation for the FDA
### @@@ Mina Tadrous, PharmD PhD – Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada ### 1062862###Co-Author###Assistant Professor###Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada###
Co-Author: Mina Tadrous, PharmD PhD – Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
### @@@ Saria Awadalla – University of Illinois Chicago, School of Public Health ### 1994592###Co-Author######University of Illinois Chicago, School of Public Health###
Co-Author: Saria Awadalla – University of Illinois Chicago, School of Public Health
### @@@ Daniel R. Touchette, PharmD, MA – University of Illinois Chicago, College of Pharmacy ### 1658080###Co-Author######University of Illinois Chicago, College of Pharmacy###
Co-Author: Daniel R. Touchette, PharmD, MA – University of Illinois Chicago, College of Pharmacy
### @@@ Glen T. Schumock – University of Illinois Chicago, College of Pharmacy ### 1994591###Co-Author######University of Illinois Chicago, College of Pharmacy###
Co-Author: Glen T. Schumock – University of Illinois Chicago, College of Pharmacy
### @@@ Todd A. Lee, PharmD, PhD – Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago ### 1657993###Co-Author######Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago###
Co-Author: Todd A. Lee, PharmD, PhD – Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago
###
The Final Word
The growing global problem of drug shortages: Understanding their impact on research, patients and healthcare systems

Mina Tadrous, PharmD PhD – Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada ### 1062862###Lead Speaker###Assistant Professor###Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada###
Lead Speaker: Mina Tadrous, PharmD PhD – Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
### @@@ Katie Suda, PharmD MS (she/her/hers) – University of Pittsburgh School of Medicine, Department of Medicine, Division of General Internal Medicine and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, ### 1360024###Speaker###Professor###University of Pittsburgh School of Medicine, Department of Medicine, Division of General Internal Medicine and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System,###
Speaker: Katie Suda, PharmD MS (she/her/hers) – University of Pittsburgh School of Medicine, Department of Medicine, Division of General Internal Medicine and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System,
### she/her/hers @@@ Anton Pottegård, PhD, DMSc – University of Southern Denmark ### 1062518###Speaker###Professor###University of Southern Denmark###
Speaker: Anton Pottegård, PhD, DMSc – University of Southern Denmark
###
The Hidden Role Of AI In Treatment Selection: Friend Or Foe To The Study And Practice Of Pharmacoepidemiology?

Harriet Dickinson, MPhil, PhD – Gilead ### 1991252###Lead Speaker###RWE Director###Gilead###
Lead Speaker: Harriet Dickinson, MPhil, PhD – Gilead
### @@@ Enriqueta Vallejo-Yagüe, PhD, Pharm – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland ### 2325322###Speaker###Advanced Postdoc and Team Lead###Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland###
Speaker: Enriqueta Vallejo-Yagüe, PhD, Pharm – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
### @@@ Katoo Muylle, MSc, PhD (she/her/hers) – AstraZeneca ### 2325323###Speaker###Real World Evidence Manager###AstraZeneca###
Speaker: Katoo Muylle, MSc, PhD (she/her/hers) – AstraZeneca
### she/her/hers @@@ Juan M. Hincapie-Castillo, PharmD, MS, PhD (he/him/his) – University of North Carolina at Chapel Hill ### 1655344###Speaker###Assistant Professor###University of North Carolina at Chapel Hill###
Speaker: Juan M. Hincapie-Castillo, PharmD, MS, PhD (he/him/his) – University of North Carolina at Chapel Hill
### he/him/his @@@ Danica Marinac-Dabic – FDA ### 1088322###Speaker######FDA###
Speaker: Danica Marinac-Dabic – FDA
###
The Masking Phenomenon: Evaluating COVID-19 Vaccine Reports and Their Impact on AE Reporting in KAERS

Suvin Park – Ewha Womans University ### 1659876###Presenting Author###Seoul, Korea###Ewha Womans University###
Presenting Author: Suvin Park – Ewha Womans University
### @@@ Na-Young Jeong, PhD – Ewha Womans University ### 1062838###Co-Author###Postdoctoral researcher###Ewha Womans University###
Co-Author: Na-Young Jeong, PhD – Ewha Womans University
### @@@ Hui-Eon Lee – Ewha Womans University ### 1660185###Co-Author######Ewha Womans University###
Co-Author: Hui-Eon Lee – Ewha Womans University
### @@@ Hee-Jin Kim, MA – Ewha Womans University ### 1063354###Co-Author###PhD student###Ewha Womans University###
Co-Author: Hee-Jin Kim, MA – Ewha Womans University
### @@@ Eunsun Lim, MS – Ewha Womans University ### 1063363###Co-Author###PhD Student###Ewha Womans University###
Co-Author: Eunsun Lim, MS – Ewha Womans University
### @@@ Nam-Kyong Choi – Ewha Womans University ### 1660178###Co-Author######Ewha Womans University###
Co-Author: Nam-Kyong Choi – Ewha Womans University
###
The nature of uncertainties on the benefit-risk balance of anticancer medicines at initial marketing authorisation in the European Union

Anne Taams, MSc – Dutch Medicines Evaluation Board ### 2325534###Presenting Author###Assessor and researcher###Dutch Medicines Evaluation Board###
Presenting Author: Anne Taams, MSc – Dutch Medicines Evaluation Board
### @@@ Carla Herberts – Department Regulatory affairs, uniQure, Amsterdam, The Netherlands ### 2325535###Co-Author######Department Regulatory affairs, uniQure, Amsterdam, The Netherlands###
Co-Author: Carla Herberts – Department Regulatory affairs, uniQure, Amsterdam, The Netherlands
### @@@ Lourens T. Bloem, PharmD, PhD (he/him/his) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University ### 1063247### Co-Author###Assistant Professor Clinical Therapeutics###Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University###
Co-Author: Lourens T. Bloem, PharmD, PhD (he/him/his) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
### he/him/his @@@ Toine Egberts – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands ### 1302793###Co-Author######Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands###
Co-Author: Toine Egberts – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
### @@@ Francesco Pignatti, MD – European Medicines Agency ### 1659375###Co-Author######European Medicines Agency###
Co-Author: Francesco Pignatti, MD – European Medicines Agency
### @@@ Nikolaos Zafiropoulos – European Medicines Agency, Amsterdam, the Netherlands ### 2325536###Co-Author######European Medicines Agency, Amsterdam, the Netherlands###
Co-Author: Nikolaos Zafiropoulos – European Medicines Agency, Amsterdam, the Netherlands
###
The Pharmacoepidemiologist's Toolbox for Professional Empowerment

Caitlin Knox, PhD MPH FISPE (she/her/hers) – Regeneron Pharmaceuticals ### 1360272###Lead Speaker###Sr Dir, Pharmacoepidemiology###Regeneron Pharmaceuticals###
Lead Speaker: Caitlin Knox, PhD MPH FISPE (she/her/hers) – Regeneron Pharmaceuticals
### she/her/hers @@@ Hope Mueller, Masters of Business – Currax Pharmaceuticals LLC ### 2344857###Speaker###Senior Vice President, Corporate Development and Strategy###Currax Pharmaceuticals LLC ###
Speaker: Hope Mueller, Masters of Business – Currax Pharmaceuticals LLC
### @@@ Vin Lo Re, III, MD, MSCE (he/him/his) – University of Pennsylvania ### 1359970###Speaker###Associate Professor of Medicine and Epidemiology###University of Pennsylvania###
Speaker: Vin Lo Re, III, MD, MSCE (he/him/his) – University of Pennsylvania
### he/him/his @@@ Lisa G. Pont, PhD, FISPE – University of Technology Sydney ### 1655255###Speaker###Professor of Pharmacy###University of Technology Sydney###
Speaker: Lisa G. Pont, PhD, FISPE – University of Technology Sydney
### @@@ Mary E. Ritchey, PhD, FISPE – CERobs Consulting ### 1994002###Speaker###Chief Scientific Officer###CERobs Consulting###
Speaker: Mary E. Ritchey, PhD, FISPE – CERobs Consulting
### @@@ Robert W. Platt, PhD (he/him/his) – McGill University ### 1358167###Speaker###Professor###McGill University###
Speaker: Robert W. Platt, PhD (he/him/his) – McGill University
### he/him/his @@@ Juan M. Hincapie-Castillo, PharmD, MS, PhD (he/him/his) – University of North Carolina at Chapel Hill ### 1655344###Speaker###Assistant Professor###University of North Carolina at Chapel Hill###
Speaker: Juan M. Hincapie-Castillo, PharmD, MS, PhD (he/him/his) – University of North Carolina at Chapel Hill
### he/him/his
The Pill-osophy of Making Medicines Safe

Hubert G. Leufkens, PhD, FISPE – University of Utrecht ### 1061394###Moderator###Emeritus Professor ###University of Utrecht###
Moderator: Hubert G. Leufkens, PhD, FISPE – University of Utrecht
### @@@ Jieni Li, MPH, PhD – University of Houston, College of Pharmacy, Department of Pharmaceutical Health Outcomes and Policy ### 1991698###Moderator###Postdoctoral Fellow###University of Houston, College of Pharmacy, Department of Pharmaceutical Health Outcomes and Policy###
Moderator: Jieni Li, MPH, PhD – University of Houston, College of Pharmacy, Department of Pharmaceutical Health Outcomes and Policy
###
The risk of cardiovascular (CV) events after initiation of SGLT2i, GLP-1RA, DPP4i, or SUs in patients with T2D and low-to-moderate CV risk

Helen Tesfaye, PharmD, MSc – Division of Pharmacoepidemiology, Dept. of Medicine, Brigham & Women’s Hospital, Harvard Medical School ### 1655578###Presenting Author###Senior Research Specialist ###Division of Pharmacoepidemiology, Dept. of Medicine, Brigham & Women’s Hospital, Harvard Medical School###
Presenting Author: Helen Tesfaye, PharmD, MSc – Division of Pharmacoepidemiology, Dept. of Medicine, Brigham & Women’s Hospital, Harvard Medical School
### @@@ Julie M. Paik, MD, ScD – Brigham and Women's Hospital ### 1655332###Co-Author######Brigham and Women's Hospital###
Co-Author: Julie M. Paik, MD, ScD – Brigham and Women's Hospital
### @@@ Caroline Alix, BA – Brigham and Women's Hospital ### 2325341###Co-Author######Brigham and Women's Hospital###
Co-Author: Caroline Alix, BA – Brigham and Women's Hospital
### @@@ Elyse C. DiCesare, BA – Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School ### 1991353###Co-Author###Research Assistant###Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School###
Co-Author: Elyse C. DiCesare, BA – Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School
### @@@ Sara J. Cromer, MD – Massachusetts General Hospital ### 1993958###Co-Author######Massachusetts General Hospital###
Co-Author: Sara J. Cromer, MD – Massachusetts General Hospital
### @@@ Brendan M. Everett, MD, MPH – Brigham and Women’s Hospital ### 1360564###Co-Author######Brigham and Women’s Hospital###
Co-Author: Brendan M. Everett, MD, MPH – Brigham and Women’s Hospital
### @@@ Robert J. Glynn, PhD, ScD – Brigham and Women's Hospital ### 1302713###Co-Author###Professor###Brigham and Women's Hospital###
Co-Author: Robert J. Glynn, PhD, ScD – Brigham and Women's Hospital
### @@@ Deborah J. Wexler, MD, MSc – Massachusetts General Hospital ### 1360566###Co-Author######Massachusetts General Hospital###
Co-Author: Deborah J. Wexler, MD, MSc – Massachusetts General Hospital
### @@@ Elisabetta Patorno, MD, DrPH (she/her/hers) – Brigham and Women's Hospital and ### 1360380###Co-Author###Associate Professor of Medicine###Brigham and Women's Hospital and###
Co-Author: Elisabetta Patorno, MD, DrPH (she/her/hers) – Brigham and Women's Hospital and
### she/her/hers
The Risk of Cardiovascular Disease in Postmenopausal Oestrogen Receptor-Positive Breast Cancer Patients Treated with Aromatase Inhibitors: A UK Population-based Study

Lauren McVicker, PhD (she/her/hers) – Centre for Public Health, Queen's University Belfast ### 1302879###Presenting Author###Postdoctoral Research Fellow###Centre for Public Health, Queen's University Belfast###
Presenting Author: Lauren McVicker, PhD (she/her/hers) – Centre for Public Health, Queen's University Belfast
### she/her/hers @@@ Christopher Cardwell, PhD – Centre for Public Health, Queen's University Belfast ### 1302789###Co-Author###Professor###Centre for Public Health, Queen's University Belfast###
Co-Author: Christopher Cardwell, PhD – Centre for Public Health, Queen's University Belfast
### @@@ Blanaid Hicks, PhD – Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland ### 1093536###Co-Author###Senior Lecturer###Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland###
Co-Author: Blanaid Hicks, PhD – Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland
### @@@ Anton Pottegård, PhD, DMSc – University of Southern Denmark ### 1062518###Co-Author###Professor###University of Southern Denmark###
Co-Author: Anton Pottegård, PhD, DMSc – University of Southern Denmark
### @@@ Úna McMenamin, PhD – Centre for Public Health, Queen's University Belfast ### 1302881###Co-Author###UKRI Future Leaders Fellow and Lecturer in Population Cancer Research###Centre for Public Health, Queen's University Belfast###
Co-Author: Úna McMenamin, PhD – Centre for Public Health, Queen's University Belfast
###
The Teratogenic Risk Impact and Mitigation (TRIM) Tool: Development of explicit criteria for teratogenicity risk mitigation programs

Celeste LY Ewig, PharmD – University of Florida ### 1657495###Presenting Author###Graduate Assistant###University of Florida###
Presenting Author: Celeste LY Ewig, PharmD – University of Florida
### @@@ Yanning Wang, MS – University of Florida, Department of Pharmaceutical Outcomes & Policy ### 1358834###Co-Author###Graduate Student###University of Florida, Department of Pharmaceutical Outcomes & Policy###
Co-Author: Yanning Wang, MS – University of Florida, Department of Pharmaceutical Outcomes & Policy
### @@@ Nicole E. E. Smolinski, PharmD – University of Florida ### 1358688###Co-Author###Graduate Student###University of Florida###
Co-Author: Nicole E. E. Smolinski, PharmD – University of Florida
### @@@ Gita A. Toyserkani, PharmD, MBA – US Food and Drug Administration ### 1360117###Co-Author###Associate Director for Research and Strategic Initiatives###US Food and Drug Administration###
Co-Author: Gita A. Toyserkani, PharmD, MBA – US Food and Drug Administration
### @@@ Cynthia LaCivita, PharmD – US Food and Drug Administration ### 1993690###Co-Author###Director Division of RIsk Managment###US Food and Drug Administration###
Co-Author: Cynthia LaCivita, PharmD – US Food and Drug Administration
### @@@ Leila Lackey – Center for Drug Evaluation and Research, U.S. Food and Drug Administration ### 2325575###Co-Author######Center for Drug Evaluation and Research, U.S. Food and Drug Administration###
Co-Author: Leila Lackey – Center for Drug Evaluation and Research, U.S. Food and Drug Administration
### @@@ Sara Eggers – Center for Drug Evaluation and Research, U.S. Food and Drug Administration ### 2325576###Co-Author######Center for Drug Evaluation and Research, U.S. Food and Drug Administration###
Co-Author: Sara Eggers – Center for Drug Evaluation and Research, U.S. Food and Drug Administration
### @@@ Thuy N. Thai, MPH, PhD (she/her/hers) – Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute ### 2325434###Co-Author###Research Scientist###Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute###
Co-Author: Thuy N. Thai, MPH, PhD (she/her/hers) – Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute
### she/her/hers @@@ Judith C. Maro, PhD – Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute ### 2325113###Co-Author###Associate Professor###Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute###
Co-Author: Judith C. Maro, PhD – Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute
### @@@ Sonja A. Rasmussen, MD – Department of Genetic Medicine, Johns Hopkins School of Medicine ### 1991648###Co-Author######Department of Genetic Medicine, Johns Hopkins School of Medicine###
Co-Author: Sonja A. Rasmussen, MD – Department of Genetic Medicine, Johns Hopkins School of Medicine
### @@@ Almut G. Winterstein, PharmD, PhD, FISPE (she/her/hers) – University of Florida, Pharmaceutical Outcomes & Policy and Center for Drug Evaluation and Safety ### 1061393###Co-Author###Distinguished Professor###University of Florida, Pharmaceutical Outcomes & Policy and Center for Drug Evaluation and Safety###
Co-Author: Almut G. Winterstein, PharmD, PhD, FISPE (she/her/hers) – University of Florida, Pharmaceutical Outcomes & Policy and Center for Drug Evaluation and Safety
### she/her/hers
The Teratogenic Risk Impact and Mitigation (TRIM) Tool: Development of Scoring Weights to Prioritize Medications for Risk Management Beyond Labelling

Judith C. Maro, PhD – Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute ### 2325113###Presenting Author###Associate Professor###Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute###
Presenting Author: Judith C. Maro, PhD – Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute
### @@@ Celeste LY Ewig, PharmD – University of Florida ### 1657495###Co-Author###Graduate Assistant###University of Florida###
Co-Author: Celeste LY Ewig, PharmD – University of Florida
### @@@ Yanning Wang, MS – University of Florida, Department of Pharmaceutical Outcomes & Policy ### 1358834###Co-Author###Graduate Student###University of Florida, Department of Pharmaceutical Outcomes & Policy###
Co-Author: Yanning Wang, MS – University of Florida, Department of Pharmaceutical Outcomes & Policy
### @@@ Nicole E. E. Smolinski, PharmD – University of Florida ### 1358688###Co-Author###Graduate Student###University of Florida###
Co-Author: Nicole E. E. Smolinski, PharmD – University of Florida
### @@@ Gita Toyerskani – Center for Drug Evaluation and Research, U.S. Food and Drug Administration ### 2325574###Co-Author######Center for Drug Evaluation and Research, U.S. Food and Drug Administration###
Co-Author: Gita Toyerskani – Center for Drug Evaluation and Research, U.S. Food and Drug Administration
### @@@ Cynthia LaCivita, PharmD – US Food and Drug Administration ### 1993690###Co-Author###Director Division of RIsk Managment###US Food and Drug Administration###
Co-Author: Cynthia LaCivita, PharmD – US Food and Drug Administration
### @@@ Leila Lackey – Center for Drug Evaluation and Research, U.S. Food and Drug Administration ### 2325575###Co-Author######Center for Drug Evaluation and Research, U.S. Food and Drug Administration###
Co-Author: Leila Lackey – Center for Drug Evaluation and Research, U.S. Food and Drug Administration
### @@@ Sara Eggers – Center for Drug Evaluation and Research, U.S. Food and Drug Administration ### 2325576###Co-Author######Center for Drug Evaluation and Research, U.S. Food and Drug Administration###
Co-Author: Sara Eggers – Center for Drug Evaluation and Research, U.S. Food and Drug Administration
### @@@ Esther H. Zhou, MD, PhD – U.S. Food and Drug Administration ### 1062973###Co-Author###Epidemiologist###U.S. Food and Drug Administration###
Co-Author: Esther H. Zhou, MD, PhD – U.S. Food and Drug Administration
### @@@ Thuy N. Thai, MPH, PhD (she/her/hers) – Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute ### 2325434###Co-Author###Research Scientist###Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute###
Co-Author: Thuy N. Thai, MPH, PhD (she/her/hers) – Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute
### she/her/hers @@@ Sonja A. Rasmussen, MD – Department of Genetic Medicine, Johns Hopkins School of Medicine ### 1991648###Co-Author######Department of Genetic Medicine, Johns Hopkins School of Medicine###
Co-Author: Sonja A. Rasmussen, MD – Department of Genetic Medicine, Johns Hopkins School of Medicine
### @@@ Almut G. Winterstein, PharmD, PhD, FISPE (she/her/hers) – University of Florida, Pharmaceutical Outcomes & Policy and Center for Drug Evaluation and Safety ### 1061393###Co-Author###Distinguished Professor###University of Florida, Pharmaceutical Outcomes & Policy and Center for Drug Evaluation and Safety###
Co-Author: Almut G. Winterstein, PharmD, PhD, FISPE (she/her/hers) – University of Florida, Pharmaceutical Outcomes & Policy and Center for Drug Evaluation and Safety
### she/her/hers
The Treatment and Prevention of Pregnancy-related Infections

Hedvig M.E Nordeng, PhD (she/her/hers) – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo (UiO), Oslo, Norway ### 1358057###Moderator###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo (UiO), Oslo, Norway###
Moderator: Hedvig M.E Nordeng, PhD (she/her/hers) – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo (UiO), Oslo, Norway
### she/her/hers @@@ Kari Furu, MPH, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway. ### 1063219###Moderator###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.###
Moderator: Kari Furu, MPH, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
### she/her/hers
The use of brain-penetrant calcium channel blockers (BP-CCBs) and risk of suicidality and hospitalization among patients with neuropsychiatric disorders: a retrospective comparative cohort study

Azza Shoaibi, PhD, MPH – Johnson & Johnson ### 1360292###Co-Author###Director###Johnson & Johnson###
Co-Author: Azza Shoaibi, PhD, MPH – Johnson & Johnson
### @@@ Justin Bohn, ScD – Johnson & Johnson ### 1991161###Presenting Author###Associate Director, Epidemiology###Johnson & Johnson###
Presenting Author: Justin Bohn, ScD – Johnson & Johnson
### @@@ David M. Kern, PhD, MS (he/him/his) – Johnson & Johnson ### 1062834###Co-Author###Sr. Director, Epidemiology###Johnson & Johnson###
Co-Author: David M. Kern, PhD, MS (he/him/his) – Johnson & Johnson
### he/him/his @@@ Michael Maher – Johnson & Johnson ### 2325320###Co-Author######Johnson & Johnson###
Co-Author: Michael Maher – Johnson & Johnson
### @@@ Amin Yakubu – Johnson & Johnson ### 2325321###Co-Author######Johnson & Johnson###
Co-Author: Amin Yakubu – Johnson & Johnson
### @@@ Dmytro Dymshyts – Johnson & Johnson ### 1994088###Co-Author######Johnson & Johnson###
Co-Author: Dmytro Dymshyts – Johnson & Johnson
###
Time Intervals between Milestones of Studies Evaluating the Effectiveness of Risk Minimisation Measures Assessed by PRAC

Sharon C.M Essink, MSc (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. ### 2327878###Presenting Author###PhD student###Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.###
Presenting Author: Sharon C.M Essink, MSc (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
### she/her/hers @@@ Inge M. Zomerdijk – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. ### 2327879###Co-Author######Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.###
Co-Author: Inge M. Zomerdijk – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.
### @@@ Thomas Goedecke – European Medicines Agency, Amsterdam, The Netherlands. ### 2330964###Co-Author######European Medicines Agency, Amsterdam, The Netherlands.###
Co-Author: Thomas Goedecke – European Medicines Agency, Amsterdam, The Netherlands.
### @@@ Sabine M.J.M. Straus – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. ### 2327880###Co-Author######Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.###
Co-Author: Sabine M.J.M. Straus – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.
### @@@ Helga Gardarsdottir, PharmD, PhD, FISPE (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands ### 1061395###Co-Author###Professor RWD for decision making on medicines###Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands###
Co-Author: Helga Gardarsdottir, PharmD, PhD, FISPE (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
### she/her/hers @@@ Marie L. De Bruin – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. ### 2327881###Co-Author######Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.###
Co-Author: Marie L. De Bruin – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
###
Time to cystoscopy after low- or high-dose aspirin initiation: A Danish nationwide cohort study

Malene Andersen, MD (she/her/hers) – Aarhus University and Aarhus University Hospital ### 2325512###Presenting Author###PhD student###Aarhus University and Aarhus University Hospital###
Presenting Author: Malene Andersen, MD (she/her/hers) – Aarhus University and Aarhus University Hospital
### she/her/hers @@@ Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital ### 1063034###Co-Author###Chief consultant, professor###Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital###
Co-Author: Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital
### @@@ Jørgen Bjerggaard Jensen – Aarhus University and Aarhus university hospital ### 2325513###Co-Author###Professor###Aarhus University and Aarhus university hospital###
Co-Author: Jørgen Bjerggaard Jensen – Aarhus University and Aarhus university hospital
### @@@ Lars Dyrskjøt – Aarhus University and Aarhus University Hospital ### 2325514###Co-Author###Professor###Aarhus University and Aarhus University Hospital###
Co-Author: Lars Dyrskjøt – Aarhus University and Aarhus University Hospital
###
Time, Time and Time Again: Disentangling Time Trends in Prescribing with Age Period Cohort Analysis, An Exemplar on the Annual Prevalence of Statin Prescribing for Males and Females in the United States (2000-2019)

Nicholas Bakewell, MSc (he/him/his) – Institute of Health Policy, Management and Evaluation ### 1992486###Presenting Author###PhD Student###Institute of Health Policy, Management and Evaluation###
Presenting Author: Nicholas Bakewell, MSc (he/him/his) – Institute of Health Policy, Management and Evaluation
### he/him/his
Time-travelling Trends

Claudia Bruno, PhD BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1062978###Moderator###Post doctoral researcher###School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###
Moderator: Claudia Bruno, PhD BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers @@@ Christos Kontogiorgis, PhD (he/him/his) – Laboratory of Hygiene and Environmental Protection, School of Medicine, Democritus University of Thrace, Aexandroupolis, Greece ### 1657664###Moderator###Assistant Professor###Laboratory of Hygiene and Environmental Protection, School of Medicine, Democritus University of Thrace, Aexandroupolis, Greece###
Moderator: Christos Kontogiorgis, PhD (he/him/his) – Laboratory of Hygiene and Environmental Protection, School of Medicine, Democritus University of Thrace, Aexandroupolis, Greece
### he/him/his
Timing and Duration of ADHD Medication Use in Pregnancy and Risk of Preterm Birth

Chaitra Srinivas, PharmD, MMSc (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway. ### 1659381###Presenting Author###PhD Candidate###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.###
Presenting Author: Chaitra Srinivas, PharmD, MMSc (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
### she/her/hers @@@ Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway. ### 1358431###Co-Author###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.###
Co-Author: Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
### @@@ Hein Stigum – Department of Community Medicine and Global Health, University of Oslo, Oslo, Norway. ### 1991298###Co-Author######Department of Community Medicine and Global Health, University of Oslo, Oslo, Norway.###
Co-Author: Hein Stigum – Department of Community Medicine and Global Health, University of Oslo, Oslo, Norway.
### @@@ Kari Furu, MPH, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway. ### 1063219###Co-Author###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.###
Co-Author: Kari Furu, MPH, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
### she/her/hers @@@ Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden. ### 1062759###Co-Author###Assistant Professor###Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.###
Co-Author: Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.
### @@@ Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden. ### 1358377###Co-Author###Associate professor###Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.###
Co-Author: Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.
### @@@ Jennifer Hutcheon – Division of Maternal Fetal Medicine, The University of British Columbia, Vancouver, Canada. ### 1991299###Co-Author######Division of Maternal Fetal Medicine, The University of British Columbia, Vancouver, Canada.###
Co-Author: Jennifer Hutcheon – Division of Maternal Fetal Medicine, The University of British Columbia, Vancouver, Canada.
### @@@ Jacqueline M. Cohen, PhD (she/her/hers) – Norwegian Institute of Public Health ### 1360547###Co-Author###Senior researcher###Norwegian Institute of Public Health###
Co-Author: Jacqueline M. Cohen, PhD (she/her/hers) – Norwegian Institute of Public Health
### she/her/hers
Treatment Patterns and Effectiveness and Safety of Anticoagulant Therapy

Tianze Jiao, PhD (he/him/his) – University of Florida College of Pharmacy ### 2328547###Moderator###Assistant Professor###University of Florida College of Pharmacy###
Moderator: Tianze Jiao, PhD (he/him/his) – University of Florida College of Pharmacy
### he/him/his @@@ Fawaz Alharbi, MSc, PhD – Saudi Food and Drug Authority ### 2329951###Moderator###Director of Drug Safety and Risk management ###Saudi Food and Drug Authority ###
Moderator: Fawaz Alharbi, MSc, PhD – Saudi Food and Drug Authority
###
Treatment strategies and their comparative effectiveness in relapse prevention after the first relapse in persons with first-episode schizophrenia

Heidi Taipale, PharmD – Niuvanniemi Hospital ### 1062908###Presenting Author###Senior Researcher###Niuvanniemi Hospital###
Presenting Author: Heidi Taipale, PharmD – Niuvanniemi Hospital
### @@@ Antti Tanskanen – Niuvanniemi Hospital ### 1658414###Co-Author######Niuvanniemi Hospital###
Co-Author: Antti Tanskanen – Niuvanniemi Hospital
### @@@ Jari Tiihonen – Karolinska Institutet ### 1659052###Co-Author###Professor###Karolinska Institutet###
Co-Author: Jari Tiihonen – Karolinska Institutet
###
Trends in Fentanyl Containing Drug Seizures and Fentanyl Related Deaths across Canada between 2020 and 2023

Ria Garg, PharmD (she/her/hers) – Leslie Dan Faculty of Pharmacy, University of Toronto ### 1992447### Co-Author###PhD Student###Leslie Dan Faculty of Pharmacy, University of Toronto###
Co-Author: Ria Garg, PharmD (she/her/hers) – Leslie Dan Faculty of Pharmacy, University of Toronto
### she/her/hers @@@ Shaleesa Ledlie, MPH (she/her/hers) – Leslie Dan Faculty of Pharmacy, University of Toronto ### 1991951###Presenting Author###PhD Candidate###Leslie Dan Faculty of Pharmacy, University of Toronto###
Presenting Author: Shaleesa Ledlie, MPH (she/her/hers) – Leslie Dan Faculty of Pharmacy, University of Toronto
### she/her/hers @@@ Pamela Leece, MD – Public Health Ontario ### 1991952###Co-Author######Public Health Ontario###
Co-Author: Pamela Leece, MD – Public Health Ontario
### @@@ Tara Gomes, PhD – Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada ### 1359899###Co-Author###Scientist###Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada###
Co-Author: Tara Gomes, PhD – Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
###
Trends in Mifepristone Dispensing in the United States: 2016–2023

Laura E. Dodge, ScD, MPH (she/her/hers) – Optum Epidemiology ### 2330509###Presenting Author###Senior Epidemiologist###Optum Epidemiology###
Presenting Author: Laura E. Dodge, ScD, MPH (she/her/hers) – Optum Epidemiology
### she/her/hers @@@ Hannah Katcoff – Optum Epidemiology ### 2330508###Co-Author######Optum Epidemiology###
Co-Author: Hannah Katcoff – Optum Epidemiology
### @@@ Laura Yochum – Optum Epidemiology ### 2327396###Co-Author######Optum Epidemiology###
Co-Author: Laura Yochum – Optum Epidemiology
### @@@ Andrea Chomistek, MPH, ScD – Optum Epidemiology ### 2327115###Co-Author######Optum Epidemiology###
Co-Author: Andrea Chomistek, MPH, ScD – Optum Epidemiology
###
Trends in the Cost and Utilization of Publicly Dispensed Respiratory Inhalers in Ontario, Canada: A Repeated Cross-Sectional Study

Ria Garg, PharmD (she/her/hers) – Leslie Dan Faculty of Pharmacy, University of Toronto ### 1992447###Presenting Author###PhD Student###Leslie Dan Faculty of Pharmacy, University of Toronto###
Presenting Author: Ria Garg, PharmD (she/her/hers) – Leslie Dan Faculty of Pharmacy, University of Toronto
### she/her/hers @@@ Tianru Wang – ICES, Toronto, Ontario, Canada ### 2325531###Co-Author######ICES, Toronto, Ontario, Canada###
Co-Author: Tianru Wang – ICES, Toronto, Ontario, Canada
### @@@ Mina Tadrous, PharmD PhD – Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada ### 1062862###Co-Author###Assistant Professor###Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada###
Co-Author: Mina Tadrous, PharmD PhD – Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
### @@@ Tony Antoniou – Li Ka Shing Knowledge Institute, St. Michael’s Hospital ### 1660981###Co-Author###Scientist###Li Ka Shing Knowledge Institute, St. Michael’s Hospital###
Co-Author: Tony Antoniou – Li Ka Shing Knowledge Institute, St. Michael’s Hospital
### @@@ Tara Gomes, PhD – Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada ### 1359899###Co-Author###Scientist###Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada###
Co-Author: Tara Gomes, PhD – Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
###